Upregulation of AnxA2 has been observed in gastric cancer, endometrial cancer, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, breast cancer, kidney renal clear cell carcinoma, high-grade prostate cancer, and glioblastoma. This evidence concerns the gene ANXA2 and hepatocellular carcinoma.